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Background: Patients undergoing caesarean delivery are at increased risk of obstetric haemorrhage.
Uterine atony has been shown to be most common aetiology (30%) for PPH in patients undergoing
caesarean delivery. Use of uterotonic agents decreases the incidence of PPH by approximately 40%
when compared with placebo. Oxytocin is the most frequently used uterotonic agent because of less
side-effects compared with all other available agents. We did the study to ﬁnd out the minimal dose
of oxytocin required to produce adequate uterine tone (UT) in primigravida women undergoing
elective caesarean delivery.
Methods: This randomized double blind study was conducted in ninety full term primigravidas
undergoing elective caesarean delivery under spinal anaesthesia. All patients received intravenous
bolus of either 0.5, 1, or 2 unit oxytocin followed by infusion of 10 unit/h. UT was assessed by a
blinded obstetrician as either adequate or inadequate, and using a ﬁve point scale, where 1 = ato-
nic, 2 = partial but inadequate contraction, 3 = adequate contraction, 4 = well contracted and
5 = very well contracted at 2, 3, 6, and 9 min after oxytocin administration. Minimum effective
doses of oxytocin were analysed. Oxytocin related side-effects (including hypotension) were
recorded.
Results: There were no signiﬁcant differences in the prevalence of adequate UT among the study
groups at 2 min (86%, 90% and 93% for, 0.5, 1 and 2 unit oxytocin, respectively). The prevalence
of nausea and vomiting was signiﬁcantly higher after 2 unit oxytocin vs 0.5 unit at 1 min (13%vs 3%).J Medical enclave, Rohtak-
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162 S. Kiran et al.Conclusion: Small bolus dosages of oxytocin (0.5–2 unit) result in adequate uterine tone in primi-
gravida women undergoing elective caesarean delivery with minimal effects on haemodynamic
parameters and less incidence of nausea and vomiting.
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Oxytocin administration is initiated immediately after umbili-
cal cord clamping at caesarean delivery. Though changes in
haemodynamics following caesarean delivery can be because
of removal of aortocaval compression, autotransfusion from
uterine contraction, blood loss, use of vasopressors and emo-
tional excitement; oxytocin has been shown to play a major
role [1,2]. Oxytocin is the ﬁrst line of drug for prophylaxis
and treatment of uterine atony. It is administered in a wide
range of doses and timing patterns. Oxytocin is the most fre-
quently used uterotonic agent because of less side-effects com-
pared with all other available agents.
The British National Formulary presently recommends that
oxytocin should be administered in a 5-IU dose by a slow
intravenous injection after delivery during caesarean section
[3]. In the US, an infusion of 10 unit at the rate of 0.02–
0.04 IU/min is recommended for postpartum haemorrhage.
A slow intravenous bolus of 5 units of oxytocin is commonly
used by obstetricians and anaesthetists (86% and 92% respec-
tively) during caesarean delivery in UK [4]. A 5 unit intrave-
nous bolus of oxytocin is also associated with signiﬁcant side
effects such as hypotension, tachycardia, ﬂushing and chest
pain [1,2]. Safety and efﬁcacy data are lacking to support the
routine dose of a 5 unit bolus of oxytocin as a standard during
elective caesarean delivery. Although some authors have com-
mented that decreasing or omitting oxytocin bolus diminishes
the haemodynamic changes [1,2], but some may concern about
poor uterine tone and resultant increased bleeding [4]. In a re-
cent publication, the authors have reviewed an approach to
dosing and choices of uterotonic agents for limitation of
PPH [5]. Recently in an editorial by Tsen and Balki it has been
suggested that oxytocin should be used in initial doses of less
than 5 unit slowly followed by an initial rapid infusion of
oxytocin followed by a maintenance infusion. Dosages of these
infusions should be low. The authors further suggested a ‘‘rule
of 3’’oxytocin protocol during caesarean delivery [6].
As the magnitude of side effects are dose related it appears
prudent to use the minimum effective dose of oxytocin.2. Methods
After approval of ethical committee ninety full term primi-
gravidas age between 18 and 35 years belonging to American
Society of Anesthesiologists (ASAs) physical status I and II,
having singleton pregnancies undergoing elective caesarean
delivery with Pfannensteil incision under spinal anaesthesia
were included in the study. Patients having any contraindica-
tions for spinal anaesthesia, active labour or with ruptured
membranes, known drug allergy to oxytocin, signiﬁcant
obstetric disease such as pregnancy-induced hypertension or
pre-eclampsia, known risk factors for postpartum haemor-rhage such as abnormal placentation or uterine ﬁbroids,
polyhydraminos, oligohydraminos and diabetes mellitus were
excluded from the study.
All the patients were examined a day before surgery and
subjected to complete general physical as well as systemic
examination. Routine investigations such as haemoglobin,
bleeding time, clotting time and urine examination were car-
ried out in all the patients. The purpose and protocol of the
study was explained to patients and informed written consent
was obtained. Patients were kept fasted for 6 h and premedi-
cated with tablet ranitidine 150 mg orally the night before
and on the morning 2 h before surgery. Upon arrival in oper-
ating room usual monitoring including non-invasive blood
pressure, EKG and pulse oximetry were established. Intrave-
nous line was secured with an 18G venous cannula and base
line haematocrit was taken. Patients were preloaded with
10 ml kg1 of Ringer lactate solution. Baseline maternal heart
rate (HR) and non-invasive blood pressure (NIBP) were re-
corded as the average of three readings. The patients were di-
vided randomly into three groups of 30 patients each using
Microsoft Excel generated allocations. Opaque envelopes con-
taining group assignments were used to ensure blinding.
Group 1 (n= 30) patients received 0.5 unit of oxytocin intra-
venous bolus. Group II (n= 30) patients received 1 unit of
oxytocin intravenous bolus. Group III (n= 30) patients re-
ceived 2 unit of oxytocin intravenous bolus. All patients were
given spinal anaesthesia in sitting position in L3/L4 or L4/
L5 space with 25G Quincke spinal needle with 1.5 ml of
0.5% hyperbaric bupivacaine with 25 lg of fentanyl. Patients
were laid supine with wedge under the right ﬂank to achieve
leftward tilt of 15. Surgery was commenced once the block
height reached T4 to cold perception using ice. The oxytocin
dose was prepared before surgery and diluted with 0.9% nor-
mal saline up to a total volume of 5 ml by a doctor not in-
volved in the care of the patient or any data recordings, so
that each anaesthetist and obstetrician were blinded to oxytocin
dose. Oxytocin was administered as an intravenous bolus
over a time period of 15 s after clamping of the umbilical cord
and delivery of the foetus. After delivery of placenta uterine
tone was assessed by the obstetrician at 2, 3, 6, and 9 min inter-
val on a ﬁve-point scale, where 1 = atonic, 2 = partial but
inadequate contraction, 3 = adequate contraction, 4 = well
contracted and 5 = very well contracted [14]. As per our insti-
tutional protocol uterine massage was not done and uterus not
exteriorised. If the tone was assessed as inadequate at 2 min, a
‘rescue’ bolus of 2.5 units of oxytocin was administered. A
maximum of two ‘rescue’ doses of oxytocin were permitted
in the event of two separate recordings of inadequate uterine
tone. If uterine tone was assessed as inadequate after two res-
cue doses of oxytocin, then additional uterotonic drugs were
administered in following order: intravenous methylergomet-
rine 0.2 mg, intramuscular carboprost tromethamine 0.25 mg
and then rectal misoprostol 800–1000 mg. After adequate uter-
ine tone had been achieved, maintenance infusion of oxytocin
Table 3 Estimated blood loss in the three groups.
Group Blood loss in ml (mean ± SD)
I (n= 30) 840.60 ± 110.44
II (n= 30) 815 ± 108.59
III(n= 30) 786.5 ± 128.79
Table 4 Preoperative and postoperative haematocrit.
Group Preop Hct
(mean ± SD)
Postop Hct
(mean ± SD)
I (n= 30) 29.166 ± 1.80 24.51 ± 2.42
II (n= 30) 28.9 ± 2.36 24.33 ± 2.68
III (n= 30) 29.03 ± 2.34 24.45 ± 2.64
Table 5 Heart rate at time of delivery and 2 min after
oxytocin bolus.
Group HR in beats/min
at time of delivery
(mean ± SD)
HR in beats/min 2 min
after oxytocin bolus
(mean ± SD)
I (n= 30) 90.76 ± 8.240 96.63 ± 9.942
II(n= 30) 89.55 ± 6.3555 95.70 ± 6.654
III(n= 30) 90.06 ± 6.113 97.46 ± 6.640
Table 6 Mean arterial pressure at time of delivery and 2 min
after oxytocin bolus.
Group MAP (mmHg)
at time of delivery
(mean ± SD)
MAP (mmHg) 2 min
after oxytocin bolus
(mean ± SD)
I (n= 30) 86.61 ± 4.874 83.10 ± 4.967
II (n= 30) 89.40 ± 4.848 82.58 ± 4.592
III (n= 30) 89.60 ± 4.538 81.18 ± 4.151
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saline at 250 ml/h [0.16 units/min]). Measurement of NIBP
and HR were taken at 2 min intervals from the time of oxyto-
cin administration. Hypotension was deﬁned as a decrease in
mean blood pressure P10% of the baseline value, and each
episode of hypotension was treated with an intravenous bolus
of 3 mg of ephedrine. Tachycardia was deﬁned as maternal
HRP 120 beats min1 or P10% of the baseline value.
The primary study outcome measure was the assessment of
either adequate or inadequate uterine tone at 2 min after
administration of the initial oxytocin dose. Secondary end-
points included the number of rescue doses of oxytocin, use
of additional uterotonic agents, intraoperative blood loss
(measured by estimating blood collected by suction and by cal-
culating the weight of blood on surgical swabs), haematocrit
values measured before surgery and within the ﬁrst 30 min
after completion of surgery. Any side effects associated with
oxytocin such as tachycardia, hypotension, nausea, vomiting,
chest pain, headache and ﬂushing were recorded.
At the end of study all the data was compiled and analysed
statistically using analysis of variance (ANOVA) test for hae-
matocrit, need for additional uterotonic agents and the
amount of blood loss. Chi-square test was used to analyse
HR, NIBP and the side effects of oxytocin.
3. Results
Ninety patients were randomised and all completed the study.
Patient characteristics i.e. age, weight, haemodynamic param-
eters before oxytocin infusion among the group were compara-
ble as shown in Table 1. The percentage of patients with
adequate UT at 2 min after bolus administration of oxytocin
are shown in Table 2. There were no signiﬁcant differences
in the prevalence of adequate UT at 2 min between the groups
(P value > 0.05).There were no signiﬁcant difference in the to-
tal number of rescue doses of oxytocin and additional utero-
tonic drugs used as shown in Table 3. There was signiﬁcant
difference in incidence of nausea and vomiting in group III
as compared to group I as shown in Table 2.II. Blood loss in
all three groups is shown in Table 3, Table 4 shows preopera-Table 1 Demographic data.
Group Weight in kgs
(mean ± SD)
Age in years
(mean ± SD)
I (n= 30) 62.20 ± 2.47 21.90 ± 2.28
II (n= 30) 60.83 ± 3.31 22.00 ± 1.93
III (n= 30) 61.90 ± 4.36 22.13 ± 2.31
Table 2 Study parameters.
Group Adequate UT
at 2 min
RDO AUD Nausea and
vomiting
I (n= 30) 26 5 (86%) 1 1
II (n= 30) 27 4 (90%) 0 2
III (n= 30) 28 3 (93%) 0 4
RDO: rescue doses of oxytocin.
AUD: additional uterotonic drugs.tive and postoperative haematocrit. The results of both are sta-
tistically comparable in all groups. No signiﬁcant hypotension
and tachycardia occurred in any patient in any group as shown
in Tables 5 and 6. Also there was no incidence of chest pain,
headache, ﬂushing or any ECG changes in any patient.
4. Discussion
Our results show that small bolus doses of oxytocin (0.5–
2 unit) result in adequate uterine tone in primigravida women
undergoing elective caesarean delivery with minimal effects on
haemodynamic parameters and less incidence of nausea and
vomiting. Adequate uterine tone was achieved with 0.5 IU of
oxytocin with less incidence of nausea and vomiting as com-
pared to 2 IU of oxytocin administration. There was no differ-
ence in the blood loss & pre and postoperative haematocrit
values between the groups.
The most important ﬁnding of our study is that in healthy
primigravida undergoing elective caesarean delivery under
spinal anaesthesia, oxytocin in the dose as small as 0.5 unit is
164 S. Kiran et al.effective in producing adequate uterine tone. The results of our
study are similar to that done by Butwick et al. [7] in which
adequate uterine tone was achieved with 0.5 unit of oxytocin
at 2 min after delivery. However, the number of patients in
their study was less and adequate uterine tone was achieved
in 93%, 87%, and 93% of the patient at the interval of 3, 6,
9 min but in our study at various intervals mean adequate uter-
ine score kept on increasing. Moreover our study was con-
ducted on primigravida.
The results of our study are similar to a previous study done
by Carvalho et al. [8] in which ED90 of oxytocin was estimated
to be 0.35 units However, their study was single-blinded; in
contrast to our study(double blinded). Moreover oxytocin re-
lated side-effects such as nausea (38%), vomiting (17%), and
ﬂushing (63%) were noted in their study, which is in contrast
to our study. The reason may be slow speed of injection of
oxytocin (15 s) in our study. Our results are comparable to an-
other study in which adequate uterine tone was achieved with
2 unit of oxytocin [9]. The results are in contrast with another
study done by Sarna et al. [10] where adequate uterine tone
was achieved with 5–20 unit of oxytocin with no difference
in estimated blood loss between the groups, but the authors
did not determine the minimum effective dose of oxytocin.
Our results are different from other two studies using very
low dose of oxytocin (0.1 and 0.29 units). Out of these the ﬁrst
study was conducted on women with cardiac disease undergo-
ing caesarean section [11]. In their study oxytocin was admin-
istered in boluses from 0.05 to 0.5 unit and adequate uterine
tone could be achieved. In the later study ED90 of oxytocin
was found to be 0.29 IU/min [12]. However, the estimate was
imprecise, as illustrated by wide ranging 95% CI (0.15–
0.43 IU/min).
The frequency of use of additional uterotonic agents was
not statistically different between the groups. We chose the
need for additional uterotonic drug as determined by surgeons
according to their usual clinical practice. This is in accordance
with previous studies [7,8].
The results of our study indicate that estimated blood loss
and difference in preoperative and postoperative haematocrit
are independent of the doses of oxytocin used which is in
accordance with previous studies [7,9,10]. In one study blood
loss was more than 1 l (marker of PPH) in all the groups using
either placebo, 0.5, 1, 3 or 5 unit bolus of oxytocin [7]. This is
in contrast to our study in which blood loss was less than 1 l in
all the groups. The difference could be because of smaller sam-
ple size and inclusion of multigravidas in their study.
In our study no hypotension was observed in any group at
any time indicating that low dosages are associated with hae-
modynamic stability during caearean delivery. These ﬁndings
are in contrast to a study in which hypotension occurred in
7% of the patients receiving 2 U of oxytocin [9]. The difference
can be because we included only primigravida in our study
whereas in their study patients were multigravida. Surprisingly
in a study using 5–20 unit of oxytocin no haemodyanamic
instability was observed. The reason can be attributed to small
patient population and infusion of oxytocin used in their study
[10].
In our study no tachycardia was observed with any of the
doses of oxytocin used. Tachycardia was observed in other
studies using higher doses of oxytocin [1,2]. However, in a
study, tachycardia was seen even in patient receiving 2 unit
of oxytocin [9]. The reason could be attributed to observationof hypotension in their study which could have produced
resultant tachycardia. Other studies examining the effect of
oxytocin did not comment upon change in heart rate [10,13].
In our study there was signiﬁcant difference in the occur-
rence of nausea and vomiting in patients receiving 2 unit of
oxytocin as compared to patient receiving 0.5 unit of oxytocin.
These results are similar to a previous study in which nausea
and vomiting occurred with 2 unit of oxytocin [9]. Our ﬁndings
are in contrast to another study done where high incidence of
nausea and vomiting (37.5% and 12.5% respectively) was ob-
served with low doses of oxytocin [8]. This can be attributed to
rapid speed of injection of oxytocin used in their study.
In our study no ﬂushing was observed in any patient. This
is similar to other studies in which no ﬂushing was observed
with low dose of oxytocin [7,9]. This observation is in contrast
to a previous study where there occured a high incidence of
ﬂushing (62.5%) with a small dose of oxytocin [8]. The authors
attributed this high incidence of ﬂushing to the potent vasod-
ilating properties of oxytocin.
No patient in our study complained of headache and light-
headedness. However, in a study headache and lightheaded-
ness was observed in 0.7% of the patient with the use of
5 unit of oxytocin [14]. The authors commented that these side
effects could be due to the coadministration of vasodilatory
drugs enhancing the adverse effect of bolus dose of oxytocin
as in their study GA was also provided to some of the patients.
Other studies using low dose of oxytocin did not comment
upon incidence of headache and lightheadedness [8,9].
Transient ECG changes (ST segment, T wave abnormali-
ties) and subjective symptoms e.g. chest discomfort and pain
has been described following 10 unit of oxytocin during caesar-
ean delivery [15]. This can be because of profound hypoten-
sion, tachycardia and coronary vasoconstiction causing
mismatch between myocardial oxygen demand and supply,
leading to myocardial ischaemia. Since we used very low dose
of oxytocin, so none of our patient experienced any ST seg-
ment or T wave changes on ECG or complained of chest pain.
We chose spinal anaesthesia as an anaesthetic technique for
our patients because general anaesthesia is a risk factor for
uterine atony [16,17]. Most of the studies investigating the oxy-
tocin dosages for uterine atony have used regional anaesthesia
except for a few where anaesthetic technique was not standard-
ised. Our study was conducted on healthy primigravida with-
out any risk factor for PPH for the purpose of homogenicity.
One limitation of our study was that we studied only primi-
gravida patients with no clinical risk factor for uterine atony.
The requirement of oxytocin may be inﬂuenced by the parity
and in patient with risk factors for uterine atony/obstetric
haemorrhage. The study was undertaken in patients undergo-
ing elective caesarean delivery. During emergency caesarean
delivery, uterine response greatly decreases; higher doses of
oxytocin with early use of alternative uterotonics may be re-
quired [13]. Also the blood loss was measured by visual assess-
ment of suction chamber, weighting the surgical swabs and by
change in preoperative and postoperative haematocrit values.
The visual estimated blood loss may be inaccurate [18] and
the changes in haemoglobin and haematocrit are difﬁcult to
interpret because of large ﬂuid shifts that occur around the
time of delivery [19]. However, most of the studies evaluating
the response of small doses of oxytocin had adopted the same
method for estimation of blood loss [7,9,14]. Another limita-
tion of our study was that uterine massage was not performed
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can be reduced further if these measures were undertaken.
In summary, our results show that small bolus doses of
oxytocin result in adequate UT at 2 min in primigravidas
undergoing elective caesarean delivery with less haemody-
namic side effects. Since the study was conducted on primi-
gravidas so the results cannot be assumed to be equivocal
for multigravidas and patient having risk factors for uterine
atony. Therefore further studies are required to assess whether
the current dosing would be adequate for high risk parturients
or for labouring women undergoing emergency caesarean
delivery as the dosing of oxytocin should be administered
according to speciﬁc patient group.References
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